Bristol-Myers Squibb Co.'s announcement of success for its PD-1 inhibitor Opdivo in the CheckMate 238 study after surgical resection in a Phase III study of melanoma patients helps pave the way for earlier treatment across tumor types, which has long been a goal of the study sponsors.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?